Brief: Daewoong Pharmaceutical Regaining Rights To Fexuprazan In The United States And Canada Upon Termination Of License Agreement With Neurogastrx
05/06/2023 16:18
Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL REGAINING RIGHTS TO FEXUPRAZAN IN
THE
UNITED STATES AND CANADA UPON TERMINATION OF LICENSE AGREEMENT
WITH NEUROGASTRX
* DAEWOONG PHARMA - EXPLORING STRATEGIC OPTIONS WITH GOAL OF
ENHANCING CLINICAL DEVELOPMENT OF FEXUPRAZAN
Source text for Eikon: ID:nPn9CX0m4a
Further company coverage: 069620.KS
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier